Sequent Scientific Limited
National Stock Exchange of IndiaTotal Valuation
Sequent Scientific Limited carries a market capitalization of 50.56B, placing it among publicly traded companies globally. Its enterprise value stands at 47.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 50.56B |
| Enterprise Value | 47.16B |
Valuation Ratios
Sequent Scientific Limited trades at a trailing price-to-earnings ratio of 158.91.
| PE Ratio | 158.91 |
| PS Ratio | 2.95 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Sequent Scientific Limited trades at an EV/EBITDA multiple of 37.46 and an EV/FCF ratio of 124.49. The EV/Sales ratio of 2.95 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.46 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.95 |
| EV / EBITDA | 37.46 |
| EV / EBIT | 37.46 |
| EV / FCF | 124.49 |
Financial Position
Sequent Scientific Limited maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 128.41, indicating elevated leverage, while an interest coverage ratio of 2.34 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.43 |
| Quick Ratio | 0.28 |
| Debt / Equity | 128.41 |
| Debt / EBITDA | N/A |
| Interest Coverage | 2.34 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 10.48 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Sequent Scientific Limited has paid 170.57M in income taxes, reflecting an effective tax rate of 29.50.
| Income Tax | 170.57M |
| Effective Tax Rate | 29.50 |
Stock Price Statistics
Sequent Scientific Limited's stock has gained approximately 36.19541% over the past 52 weeks. The 50-day moving average sits at 211.13, while the 200-day moving average is 192.60.
| Beta (5Y) | N/A |
| 52-Week Price Change | 36.19541% |
| 50-Day Moving Average | 211.13 |
| 200-Day Moving Average | 192.60 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sequent Scientific Limited generated 15.98B in revenue and converted that into 296.78M in net income, yielding earnings per share of 1.57. EBITDA reached 1.26B, while operating income came in at 1.26B.
| Revenue | 15.98B |
| Gross Profit | 7.14B |
| Operating Income | 1.26B |
| Pretax Income | 578.26M |
| Net Income | 296.78M |
| EBITDA | 1.26B |
| EBIT | 1.26B |
| Earnings Per Share (EPS) | 1.57 |
Margins
Sequent Scientific Limited operates with a gross margin of 44.66, reflecting its pricing power and cost economics. The operating margin of 7.88 and net profit margin of 1.86 provide insight into operational efficiency.
| Gross Margin | 44.66 |
| Operating Margin | 7.88 |
| Pretax Margin | 3.62 |
| Profit Margin | 1.86 |
| EBITDA Margin | 7.88 |
Scores
Sequent Scientific Limited posts an Altman Z-Score of 7.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.73 |